Ixazomib in the management of relapsed multiple myeloma

Abstract : The development of proteasome inhibitors contributed to the dramatic life expectancy improvement observed in myeloma patients over the past decades. Ixazomib is a boron-containing selective and reversible proteasome inhibitor that demonstrated antimyeloma activity with excellent safety profile. Ixazomib is the first orally available proteasome inhibitor approved in combination with lenalidomide and dexam-ethasone for the treatment of myeloma patients who received at least one prior therapy. The present review addresses the current knowledge regarding the clinical use of ixazomib in relapsed myeloma patients .
Document type :
Journal articles
Complete list of metadatas

Cited literature [32 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01934497
Contributor : Elizabeth Bernardo <>
Submitted on : Monday, November 26, 2018 - 8:54:49 AM
Last modification on : Monday, May 20, 2019 - 3:32:02 PM
Long-term archiving on : Wednesday, February 27, 2019 - 12:54:04 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Cyrille Touzeau, Philippe Moreau. Ixazomib in the management of relapsed multiple myeloma. Future Oncology, Future Medicine, 2018, 14 (20), pp.2013 - 2020. ⟨10.2217/fon-2017-0710⟩. ⟨inserm-01934497⟩

Share

Metrics

Record views

127